- recruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
United States · Australia · Canada - active not recruitingPHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
This study is for people who have had surgery for bile duct cancer. It's testing a new medicine called rilvegostomig with chemotherapy, to see if it stops the cancer from coming back. It compares the new medicine to a dummy pill.
United States · Australia · Belgium - active not recruitingPHASE3
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
This study is looking at a new drug called durvalumab, combined with standard chemotherapy, for people with advanced bile duct cancer. It aims to see if this combination is safe and works better than current treatments in shrinking tumours and improving health.
United States · France · Germany - recruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
United States · Australia · Austria - recruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer
This study is looking at new treatments for a type of cancer called biliary tract cancer after surgery. It combines existing cancer drugs with new immunotherapy drugs, durvalumab and tremelimumab. The aim is to see if these combinations can stop the cancer from coming back and improve how long people live well.
Germany - recruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
United States · Argentina · Belgium - active not recruitingPHASE2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
This study looks at new treatments (ramucirumab or merestinib) combined with standard chemotherapy for people with advanced biliary tract cancer. It aims to see how well these new drug combinations work and if they are safe.
United States · Argentina · Australia - active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
United States · China · Hong Kong - recruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
United States · Australia · Canada - recruitingPHASE2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
This study tests a new medicine called ivonescimab for advanced bile duct cancer. It's for patients who previously took part in the SAFIR-ABC10 study but didn't get the experimental treatment, and whose cancer has progressed after initial chemotherapy. We want to see if ivonescimab works better than standard chemotherapy.
France · United Kingdom - active not recruitingPHASE1, PHASE2
Study for AZD4360 in Participants With Advanced Solid Tumours
This study is testing a new drug, AZD4360, for people with advanced stomach, bile duct, or pancreatic cancers that have a specific marker called CLDN18.2. It aims to see how safe it is and if it helps shrink tumors.
United States · China · Germany - recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - recruitingPHASE3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
This study is looking at new ways to treat advanced bile duct cancer. It compares two drug combinations: rilvegostomig with chemotherapy, and durvalumab with chemotherapy, to see which is safer and works better as a first treatment.
United States · Australia · Belgium - recruitingNA
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
This study looks at a blood test (Marsden360 ctDNA) for people with certain cancers. It checks if the test helps doctors find the best treatments or clinical trials, and if it makes personalised cancer care better within the NHS.
United Kingdom